Skip to navigation Skip to content

Refractory follicular B-cell non-Hodgkin's lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051115

Expand/Collapse all sectionsExpand all


This document outlines details of the previous Pharmaceutical Benefits Scheme (PBS) subsidised idelalisib for patients with Refractory follicular B-cell non-Hodgkin's lymphoma (FBHL).

This program has been moved to the general schedule from 1 January 2022 and this page is for informational purposes only.

Refractory follicular B-cell non-Hodgkin’s lymphoma and listing dates

Refractory follicular B-cell non-Hodgkin’s lymphoma (FBHL) is a type of blood cancer.

Listing dates are as follows:

  • idelalisib - 1 September 2017

See Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA) for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS authority approvals line.

The Resources page contains links to contact details, the Pharmaceutical Benefits Scheme (PBS) and Services Australia website.

Process telephone Authority approval application

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)